News
-
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
BioVersys Receives Green Light from US FDA for BV100 HABP/VABP Phase 3 Pivotal Trial Start
BioVersys receives US FDA green light for BV100 HABP/VABP Phase 3 pivotal trial start to address CRABC infections in hospital-acquired bacterial pneumonia. A significant step in developing novel antibacterial products for MDR bacteria -
-
COMMUNIQUÉ DE PRESSE
85% of banks’ corporate clients plan to engage with a non-bank financial institution within the next year as competition with private capital intensifies
85% of banks' corporate clients plan to engage with non-bank financial institutions in the next year as competition intensifies. Capgemini's report emphasizes the need for CIBs to innovate through technology and culture -
-
